CRA consultants were commissioned by the European Federation of Pharmaceutical Industries and Associations (EFPIA) to conduct an independent and objective assessment of the impact on the life sciences industry in Europe of a withdrawal of the United Kingdom from the European Union (commonly described as British exit from the EU or “Brexit”). The broad goal of this project was to identify, from both a UK and a European perspective, the positive and negative impact that a change in the relationship might have upon activities along the industry’s value chain.
To read the report, click the link below.
Government Scorekeepers Likely Underestimate the Impact of Lower Drug Costs Now Act (H.R.3) on Investment in Innovative Medicines: Brief
The Congressional Budget Office (CBO), which is charged with calculating the costs of potential legislation to guide policymaking, estimated that if H.R.3 were...